黑德拉基宁通过向基化酶9A减轻心脏重塑
Liqian Chen1,2,3, Xinghong Zhou2, Yanting You2
1Department of Traditional Chinese Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Phytotherapy research : PTR
|February 26, 2026
概括
原 (HED) 抑制基化酶9A (PDE9A),激活循环氨酸单酸蛋白激酶G (cGMP-PKG) 途径. 这种天然化合物可以改善心脏缩和纤维化,提供潜在的心力衰竭治疗.
科学领域:
- 心血管生物学 心血管生物学
- 药理学 药理学是指药理学的学科.
- 自然产品 化学 化学
背景情况:
- 心力衰竭需要新的治疗策略.
- 循环瓜诺辛单酸盐 (cGMP) - 蛋白激酶G (PKG) 途径是心脏保护性的.
- 目前用于心脏重塑的固酶9A (PDE9A) 抑制剂缺乏临床可用性.
研究的目的:
- 为了研究Hederagenin (HED) 对心脏重塑的影响.
- 阐明心脏中HED的分子标和机制.
主要方法:
- 利用细胞,斑马鱼和小鼠模型来评估HED对心脏缩的影响.
- 雇佣了HuProt v4.0 20K人类蛋白质组微阵列来识别HED的分子目标.
- 通过表面等离子体共振 (SPR),分子对接和位点定向突变发生,验证了目标参与和机制.
主要成果:
- 原 (HED) 在体外和体内显著减轻心脏缩和纤维化.
- 蛋白质组微阵列分析确定基化酶9A (PDE9A) 是HED.的直接分子标.
- HED的保护作用是由PDE9A抑制的介导,导致循环氨酸单酸蛋白激酶G (cGMP-PKG) 途径的激活.
结论:
- 原 (HED) 作为一种新型的基化酶9A (PDE9A) 抑制剂.
- 通过激活cGMP-PKG信号通路,HED可以改善心脏缩反应.
- HED为心力衰竭治疗提供了一个有前途的治疗候选者.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
663
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
663
Heart Failure V: Medical Management
419
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
419
Transducer Mechanism: Enzyme-Linked Receptors
4.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
4.5K
Heart Failure Drugs: Diuretics
1.1K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K
Heart Failure II: Pathophysiology
1.1K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.1K


